奥美拉唑预防晚期胃癌患者化疗消化道反应的作用分析

Analysis the effect of Omeprazole prevent gastrointestinal reaction for late phase gastric cancer patients who received chemotherapy

目的 探讨奥美拉唑在术后胃癌患者化疗中的作用.方法 将确诊为胃癌且已行手术治疗及具有化疗适应症的患者68例,随机分成治疗组和对照组.对照组34例按常规方案化疗,两组化疗前30分钟均给予盐酸恩丹西酮注射液8mg静脉注射预防消化道反应;治疗组80例在常规治疗的基础上,化疗前1天开始每日静脉给予奥美拉唑40mg,用至化疗结束后2天,观察患者的进食量、恶心、呕吐情况.结果 治疗组和对照组Ⅱ～Ⅲ度进食量变化发生率分别为分别为26.5%和41.2%,两组比较差异有统计学意义（P＜0.05）;治疗组和对照组Ⅱ～Ⅲ度呕吐发生率分别为20.6%和35.3%,两组比较差异有统计学意义（P＜0.05）.结论 奥美拉唑可明显减轻术后胃癌患者化疗引起的胃肠道不良反应及其对患者食欲的影响,可提高化疗患者的生活质量及治疗依从性.

Objective To investigate the effect of omeprazole on gastric cancer patients who accepted chemotherapy after operation. Methods 68 cases diagnosed gastric cancer who received operation and can accept chemotherapy were divided into study group and control group. The 34 patientsin control group were received conventional chemotherapy. Both groups wereintravenous injected with ondansetron 30 minutes before chemotherapy at the dose of 8mg to prevent gastrointestinal reaction. Patients （ n = 34 ） in the study group wereintravenous injected with 40 mg omeprazole from the day beforechemotherapy to the 2nddayafterchemotherapy. The conditions of appetite, nausea and sickness were observed. Results The incidence of grade Ⅱ/Ⅲ food intakechange for study groupand control group were 26.5% and 41.2% separately, the difference between the two groups present statistically significant （ P 〈 0. 05 ）. The incidence of grade I[ / m vomiting change for study group and the control group were 20.6% and 35.3% separately, the difference between the two groups was statistically significant （ P 〈 0. 05）. Conclusions Omeprazole can significantly reduce theadverse gastrointestinal reactions for gastric cancer patients who received chemotherapy and improvepatients＇ appetite, also, can improve the patients＇life quality and compliance.